StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 4.7
Power Rank trend -> Falling
07/26/2024 16:24:00 EST
Eli Lilly and Company (LLY)
Industry: Drug Manufacturers - General
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, LLY has been trading in a range between $950.46 and $848.90 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Eli Lilly and Company $LLY entered a Red zone 3 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $603.57, a potential down side of -24.99% from the recent price of 804.62. The stock is trading 20.07% (potential upside) below its 52 week high of $966.10 and 81.39 % (potential downside) above its 52 week low of $443.58 - based on the recent price.
Company Summary
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
News
| MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm! NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF. Source: Accesswire Fri, 26 Jul 2024 15:45:00 -0400 Sentiment: Neutral |
| Pharmaceutical stocks to watch for end of 2024 Pharma stocks can be strong investments regardless of economic conditions, as this stability arises because the demand for medications and healthcare services remains steady, even when prices rise. Source: Finbold Fri, 26 Jul 2024 09:53:26 -0400 Sentiment: Positive |
| Watch These Eli Lilly Stock Price Levels as Weight-Loss Drug Competition Rises Eli Lilly (LLY) shares dropped more than 4% on Thursday, continuing a hasty retreat from their record high earlier this month, as investors assessed the possible impact of a promising new weight-loss injection developed by Viking Therapeutics (VKTX) on the drugmaker's own weigh anti-obesity drug, Mounjaro. Last week, Eli Lilly shares tumbled after Swiss pharmaceutical firm Roche Holding AG said its new non-injectable weight-loss drug has shown encouraging early stage data. Source: Investopedia Fri, 26 Jul 2024 08:16:04 -0400 Sentiment: Positive |
| Prediction: This Is What Eli Lilly Stock Will Do Next Eli Lilly has been a favorite among pharmaceutical stock investors thanks to its success in the GLP-1 space. With the stock closing in on $900 per share, I think there is a case to be made for a stock split ahead. Source: The Motley Fool Fri, 26 Jul 2024 07:45:00 -0400 Sentiment: Positive |
| Is Eli Lilly Stock Headed Toward $1300 Levels? Eli Lilly stock (NYSE: LLY) has seen its stock rise by around 50% this year, outperforming the broader indices, with the S&P 500 up over 15%. The stock now trades at 63x projected 2024 earnings of $13.75 per share. Source: Forbes Fri, 26 Jul 2024 07:00:43 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 966.1 52 Week Low: 443.5768 Beta: 0.409 50 Day MA: 864.5628 200 Day MA: 721.735 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0.664 Qtr Revenue Growth YOY: 0.26 Forward PE: 60.241 Trailing PE: 117.9795